FDA clears investigational new drug application for inhaled nicotine replacement therapy
The FDA has cleared an investigational new drug application for the RespiRx Nicotine Inhaler (QN-01), an inhaled nicotine replacement therapy, according to a press release.With this authorization, the release says that the product’s manufacturer, Qnovia, now seeks to establish the pharmacokinetic, safety and tolerability profiles of the RespiRx Nicotine Inhaler in current adult smokers vs.